Compare Charles River Laboratories Intl. Inc (CRL) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs VanEck Gold Miners ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $229.64 (market cap $11.14B), while VanEck Gold Miners ETF trades at $74.18. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| CRL | GDX | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | — |
52-Week High | $233.60 | $115.84 |
52-Week Low | $145.57 | $51.15 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GDX, the VanEck Gold Miners ETF, trades at $73.37, down 2.86% in the last 24 hours amid a bearish technical signal from moving averages. The fund's valuation metrics are not available, but recent news highlights competition from lower-fee gold ETFs and a recent addition of Aya Gold & Silver to its holdings. Technical indicators show neutral oscillators with key support at $71 and resistance at $74.
The outlook for GDX is cautious due to underperformance versus physical gold and higher volatility. Investment opportunities lie in potential gold price rebounds and record-high free cash flow yields, but risks include fee disadvantages and sector-specific volatility. Analyst sentiment is mixed, with some seeing a buying opportunity amid low valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
